| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Cellular and Molecular Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Hepatic fibrosis is a common outcome of a variety of chronic liver diseases. Here we evaluated the therapeutic efficacy of hepatocyte growth factor (HGF) on liver fibrosis induced by bile duct ligation (BDL) and investigated potential mechanisms. Mice underwent BDL, followed by intravenous injections of naked HGF expression plasmid or control vector. HGF gene therapy markedly ameliorated hepatic fibrotic lesions, as demonstrated by reduced 
-smooth muscle actin (SMA) expression, attenuated deposition of type I and type III collagen, and normalized total hydroxyproline content. HGF also suppressed transforming growth factor-ß1 (TGF-ß1) expression. Interestingly, colocalization of SMA and cytokeratin-19 in bile duct epithelium was observed, suggesting the possibility of biliary epithelial to myofibroblast transition after BDL. Cells that were still positive for cytokeratin-19 but actively producing type I collagen were found in the biliary epithelia and periductal region. Laminin staining revealed an impaired basement membrane of the bile duct epithelium in diseased liver. These lesions were largely prevented by HGF administration. In vitro, treatment of human biliary epithelial cells with TGF-ß1 induced SMA and fibronectin expression and suppressed cytokeratin-19. HGF abolished the phenotypic conversion of biliary epithelial cells induced by TGF-ß1. These results suggest that HGF ameliorates hepatic biliary fibrosis in part by blocking bile duct epithelial to mesenchymal transition.
This article has been cited by other articles:
 |
|
 |
|
  T. Kisseleva and D. A. Brenner Fibrogenesis of Parenchymal Organs Proceedings of the ATS, April 15, 2008; 5(3): 338 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kisseleva and D. A. Brenner Mechanisms of Fibrogenesis Experimental Biology and Medicine, February 1, 2008; 233(2): 109 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, Y. S. Kang, C. Dai, L. P. Kiss, X. Wen, and Y. Liu Epithelial-to-Mesenchymal Transition Is a Potential Pathway Leading to Podocyte Dysfunction and Proteinuria Am. J. Pathol., February 1, 2008; 172(2): 299 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D E J Jones Pathogenesis of primary biliary cirrhosis Postgrad. Med. J., January 1, 2008; 84(987): 23 - 33. [Full Text] [PDF]
|
|
|
|
|
|
Y. Sato, K. Harada, S. Ozaki, S. Furubo, K. Kizawa, T. Sanzen, M. Yasoshima, H. Ikeda, M. Sasaki, and Y. Nakanuma Cholangiocytes with Mesenchymal Features Contribute to Progressive Hepatic Fibrosis of the Polycystic Kidney Rat Am. J. Pathol., December 1, 2007; 171(6): 1859 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E J Jones Pathogenesis of Primary Biliary Cirrhosis Gut, November 1, 2007; 56(11): 1615 - 1624. [Full Text] [PDF]
|
|
|
|
|
|
B. Hinz, S. H. Phan, V. J. Thannickal, A. Galli, M.-L. Bochaton-Piallat, and G. Gabbiani The Myofibroblast: One Function, Multiple Origins Am. J. Pathol., June 1, 2007; 170(6): 1807 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y N Kallis, M R Alison, and S J Forbes Bone marrow stem cells and liver disease Gut, May 1, 2007; 56(5): 716 - 724. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gazdhar, P. Fachinger, C. van Leer, J. Pierog, M. Gugger, R. Friis, R. A. Schmid, and T. Geiser Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis Am J Physiol Lung Cell Mol Physiol, February 1, 2007; 292(2): L529 - L536. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
